Artelo Biosciences shares jump 10.43% premarket as Medicare CBD pilot and ART12.11 human trials progress drive optimism.

Artelo Biosciences surged 10.43% in premarket trading following the White House’s Dec. 23, 2025, Executive Order establishing a Medicare CBD reimbursement pilot. The company highlighted its proprietary ART12.11 cocrystal, a non-controlled CBD formulation with superior bioavailability and pharmacokinetics, as well-positioned to benefit from the initiative. Artelo emphasized ART12.11’s readiness for human trials, regulatory feedback, and alignment with federal data-driven healthcare goals. The announcement underscored the product’s potential to address gaps in CBD standardization and access, aligning with the pilot’s focus on improving patient care through rigorous scientific validation. CEO Gregory Gorgas highlighted the order as validation of medical CBD’s therapeutic potential and a catalyst for broader reimbursement pathways, reinforcing investor optimism.